Cardiology

Differences in Lp(a) level distribution across the diverse US Hispanic or Latino population may have important implications for its use in ASCVD risk assessment.

Ahead of the sotagliflozin approval, Deepak Bhatt, MD, MPH, offers perspective into potential future research opportunities for the SGLT1/2 inhibitor and discusses the impact of a 3rd agent boasting SGLT2 inhibition receiving approval for heart failure.

The FDA approval of sotagliflozin (Inpefa) for the treatment of heart failure was announced by Lexicon Pharmaceuticals on May 26, 2023.

A posthoc analysis of the EMPEROR-Preserved trial suggested empagliflozin decreased the risk of heart failure hospitalization or cardiovascular death, regardless of background diuretic status.

An analysis of the UK Biobank found menstrual cycles less than 21 days or longer than 35 days were associated with a 19% higher risk of CVD compared with a regular menstrual cycle length.

Data from the open-label extension period of the APOLLO-B trial provide new insight into the benefits of patisiran in patients with ATTR amyloidosis with cardiomyopathy.

An analysis of data from the NODE-303 trial provides insight into the effects of etripamil nasal spray in people with atrial fibrillation with rapid ventricular rates.

Presented at ESC HFA 2023, results of PARAGLIDE-HF detail the effects of sacubitril/valsartan on NT-proBNP and multiple clinical outcomes, relative to valsartan alone, in patients with HFmrEF or HFpEF.

An analysis of data from donors within the UNOS network suggests donor hearts from patients who were COVID-19 who were COVID-19 positive could place patients at increased risk of mortality.

Our latest cardiology case report from Brady Pregerson, MD, features a woman in her 60s with a history of sick sinus syndrome presenting with palpitations, SOB, and lightheadedness. Can you determine the correct diagnosis?

An analysis of the National Inpatient Sample offers a deep dive into the risk of adverse outcomes associated with presence of polymyositis or dermatomyositis among patients with congestive heart failure.

Data show older age, being female, having a high BMI, smoking, comorbidities, and previous hospitalization or ICU admission with COVID-19 were associated with an increased risk of developing Post-COVID-19 condition.

Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!

Leveraging data from the UK Biobank study, a new study offers insight into the risk of new-onset heart failure based on female reproductive risk factors among a cohort more than 220,000 women.

An analysis of data from more than 119,000 pregnancies suggests women with prenatal depression were at increased risk for multiple forms of cardiovascular disease within the first 2 years following delivery relative to their counterparts without prenatal depression.

A study of more than 3000 Mediterranean adults is shedding light on the impact of longer midday naps on risk of metabolic syndrome, fasting glucose, and diastolic blood pressure.

While age and fat mass were inversely associated with cardiorespiratory fitness (CRF), the physical activity index was positively associated with CRF.

New data from the POISE-3 trial indicates adherence to a preoperative hypotension avoidance strategy was no more effective than a hypertension-avoidance strategy for reducing risk of postoperative adverse events.

An analysis of data from 3 European countries provides insight into the apparent increase in risk of atrial fibrillation associated with preterm births as well as LGA or SGA births.

In patients hospitalized with acute coronary syndrome and metabolic syndrome, obstructive sleep apnea was associated with an increased risk of major adverse cardiovascular and cerebrovascular events in women, but not in men.

Patients who had severe COVID-19 infection requiring mechanical ventilation had a 16-fold risk of ventricular tachycardia within 6 months, according to new findings presented at EHRA 2023.

Using data from 4 major phase 3 trials and the Global Burden of Disease Report, investigators detail the potential impact of optimal prescription of SGLT2 inhibitors in heart failure by estimating the number of worsening heart failure events and cardiovascular deaths prevented or postponed as a result of uptake.

More than 50,000 patients with atrial fibrillation experienced reduced risks of stroke if they started statins within a year of diagnosis, compared with those who did not.

Results from the TEMPO-HCM study suggest that 30-day ECG monitoring in patients with HCM detects more arrhythmias than the standard 24-48 hours.

Using data from more than 800 older patients, new research is shining a light on the potential reduction in cognitive decline seen with the use of catheter ablation among patients with atrial fibrillation relative to medical management.

The statement suggests the importance of including non-biological factors and social determinants of health in CVD risk assessment for women of diverse races and ethnicities.

A systematic review and meta-analysis detail the unadjusted odds of developing chemotherapy-related cardiotoxicity among patients who are Black or of African ancestry relative to their White counterparts.

A double-blind, repeated crossover trial suggests personalized treatment for blood pressure could yield an additional 4.4 mmHg reduction in systolic blood pressure.

A new analysis suggests an association between elevated heart rate and increased risk of developing new-onset T2D, but the effects were largely restricted to younger individuals.